Humacyte is trading at $0.67 (6.2% up) in pre-market, bouncing back after yesterday’s profit-taking drop that followed its FDA Investigational New Drug clearance rally.
- The stock is reacting to prior company-specific momentum rather than fresh headlines this morning, with no new filings or news appearing overnight.
- Broader market sentiment remains mixed as index futures fluctuate ahead of upcoming Federal Reserve commentary.